Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 51 to 100 of 8162 results

  1. Resource planner

    Our tool to help you plan for and implement NICE guidance. View upcoming guidance and understand the impact of guidance on your resources.

  2. Lung cancer: diagnosis and management (NG122)

    This guideline covers diagnosing and managing non-small-cell and small-cell lung cancer. It aims to improve outcomes for patients by ensuring that the most effective tests and treatments are used, and that people have access to suitable palliative care and follow-up.

  3. Board

    Our board sets out our strategic priorities and policies.

  4. Resource impact of NICE guidance

    We estimate the costs or savings (budget impact) associated with technologies and guidelines so you can plan for and implement guidance.

  5. Patient Access Schemes Liaison Unit

    The Patient Access Schemes Liaison Unit (PASLU) works with companies who are considering a patient access scheme for their drug or treatment. Patient

  6. Digital technologies for delivering multidisciplinary weight-management services: early value assessment (HTE14)

    Early value assessment (EVA) guidance on digital technologies for delivering multidisciplinary weight-management services....

  7. NICE publishes final draft guidance on Enhertu after commercial discussions conclude without a price to make it a cost-effective use of NHS resources.

    NICE has published final draft guidance that does not recommend Enhertu (also called trastuzumab deruxtecan and made by Daiichi Sankyo) for treating advanced HER2-low breast cancer in adults.

  8. Vitamin B12 deficiency in over 16s: diagnosis and management (NG239)

    This guideline covers recognising, diagnosing and managing vitamin B12 deficiency in people aged 16 and over, including deficiency caused by autoimmune gastritis. It also covers monitoring for gastric cancer in people with autoimmune gastritis.

  9. Epcoritamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments (TA954)

    Evidence-based recommendations on epcoritamab (Tepkinly) for treating relapsed or refractory diffuse large B-cell lymphoma in adults after 2 or more systemic treatments.

  10. Get involved

    We want you to tell us what matters to you, your organisation or your community.

  11. NICE training and development opportunities

    To help us understand the needs of our users we are offering the opportunity to be directly involved in the work we do. Fellows, registrars and...

  12. How to apply to join a committee

    We're excited that you're interested in joining a committee and helping us improve health and social care services. By joining, you'll have the...

  13. Digital technologies for managing non-specific low back pain: early value assessment (HTE16)

    Early value assessment (EVA) guidance on digital technologies for managing non-specific low back pain in people 16 years and over....

  14. New treatment option available today for womb cancer

    A new treatment option given with chemotherapy is recommended for some types of advanced or recurrent womb cancer in final draft NICE guidance published today.

  15. Admission rates due to heart failure in people with diabetes

    Admission rates due to heart failure in people with diabetes Subject(s): Diabetes Date of publication: 01 August

  16. What professional members do

    All our committees include experienced professionals with knowledge of a particular topic within health or social care . Professional members also...

  17. Our committees

    Find out more about being on a committee at NICE.

  18. A public consultation on our new approach to prioritising guidance is now open

    Running for 4 weeks, the consultation seeks your views about our plans to make topic selection and prioritisation more integrated, effective and timely.

  19. Life sciences: how to get your product to market

    Support for industry to engage with NICE during all stages of health technology development

  20. Achieving and demonstrating compliance with NICE TA and HST guidance

    The NHS and patients need evidence that commissioners are funding medicines and treatments approved through the NICE Technology Appraisal (TA) or...

  21. Supporting the health and care system in improving productivity

    Recovering core services and improving productivity is an immediate priority for the NHS. To help, we’ve put all our relevant guidance and recommendations supporting this work in one place.

  22. Patient decision aids

    PDAs help people decide on healthcare options. They provide evidence-based information on the options available, along with likely outcomes, benefits,

  23. Indicators

    Our indicators measure outcomes that reflect quality of care. They also look at processes that are linked by evidence to improved outcomes. All our...

  24. Diagnostics advisory committee

    Our diagnostics assessment recommendations are prepared by an independent advisory committee called the diagnostics advisory committee (DAC). Standing

  25. Quality standards advisory committee

    The quality standards advisory committees (QSAC) are independent committees that help to develop our quality standards . Come to a meeting Committee

  26. Endoscopic sleeve gastroplasty for obesity (IPG783)

    Evidence-based recommendations on endoscopic sleeve gastroplasty for obesity. This involves using an endoscopic device to fold the stomach in on itself and stitch it together to reduce its volume.

  27. Help us improve

    Help us improve NICE: take part in research to help us develop better products and services.

  28. Up to 14,000 people could benefit from the first treatment for severe alopecia recommended by NICE

    New one-a-day tablet for people with severe hair loss due to alopecia areata recommended by NICE

  29. Committee B members

    Find out more about the NICE technology appraisal advisory committee B members and their registered interests

  30. Highly specialised technologies evaluation committee members

    Highly specialised technologies evaluation committee members

  31. Patient safety

    Our guidelines make evidence based, best practice recommendations. These help to improve patient safety and reduce the risk of harm across the health system.

  32. Health technology evaluation manual

    The methods, processes and topic selection manuals cover: how we choose medicines and other health technologies to evaluate (topic selection) the...

  33. Implementing NICE guidance

    Putting our guidance into practice benefits patients and carers, healthcare professionals and organisations. Teams within NICE have a role in...

  34. Talazoparib for treating HER2-negative advanced breast cancer with germline BRCA mutations (TA952)

    Evidence-based recommendations on talazoparib (Talzenna) for HER2-negative, locally advanced or metastatic breast cancer with germline BRCA1 or BRCA2 mutations in adults.

  35. NICE voluntary and community sector forum

    Help make a difference on behalf of the people most affected by our recommendations. The voluntary and community sector forum brings together...

  36. Highly specialised technologies evaluation committee

    Our recommendations on the use of highly specialised technologies are made by an independent advisory committee. This is called the highly specialised

  37. Early Value Assessment (EVA) for medtech

    NICE is trialling an innovative new approach to the way digital products, devices and diagnostics are assessed.

  38. Tuberculosis (NG33)

    This guideline covers preventing, identifying and managing latent and active tuberculosis (TB) in children, young people and adults. It aims to improve ways of finding people who have TB in the community and recommends that everyone under 65 with latent TB should be treated. It describes how TB services should be organised, including the role of the TB control board.

  39. Share your views and experiences of NICE

    We want to better understand views and experiences of NICE, from our audiences.

  40. Our programmes

    The different types of health, public health and social care information provided by NICE.

  41. Cost saving guidance

    NICE guidance that could generate cost savings.

  42. Biosimilar technologies: NICE position statement - information for the public

    Biosimilar medicines – NICE's approach A biological medicine is any medicinal product made by or derived from a biological (natural) source, for...

  43. Chemotherapy dose standardisation: NICE position statement

    NICE has been collaborating with NHS England on the Chemotherapy Dose Standardisation initiative which has been developed by the Medicines...

  44. Biosimilar technologies: NICE position statement

    There are 2 different points of the lifecycle of a NICE Technology Appraisal at which consideration of reference to or inclusion of a biosimilar is...

  45. Participation in clinical trials and subsequent access to drugs appraised by NICE: a statement on the applicability of technology appraisal guidance

    Patients taking part in clinical trials may receive drugs which have been evaluated by NICE technology appraisal guidance. Queries have been raised...

  46. Technology appraisals - Position statements

    On this page, you'll find all our position statements relating to technology appraisals. Biosimilar technologies: NICE position statement Biosimilar

  47. Into practice

    Tools and resources to help you implement guidance and quality standards at work.

  48. System implementation team

    We work with organisations to help to put our guidance into practice. We work with NHS, local authority and other organisations in their area,...

  49. Medtech innovation briefings

    Please note, from April 2023 NICE will no longer produce Medtech Innovation Briefings (MIBs) on behalf of NHS England. MIBs were commissioned by NHS...

  50. Transparency of spend

    NICE transparency of spend